Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
myelodysplastic syndrome (MDS)
Pharma
FDA considers 'regulatory action' for bluebird's Skysona
The FDA is investigating reports of patients developing blood cancer after receiving bluebird bio’s Skysona and is considering regulatory action.
Kevin Dunleavy
Dec 2, 2024 11:22am
FDA signs off on Geron's long-awaited blood cancer drug Rytelo
Jun 7, 2024 12:03pm
ASCO: BMS' $4B plan for Reblozyl takes shape—with one caveat
May 25, 2023 5:00pm
